Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. Academic Article uri icon

abstract

  • Six dogs were entered into a 30-day, prospective, nonrandomized, uncontrolled clinical trial evaluating the effects of an oral preparation of budesonide on the hypothalamic-pituitary-adrenal (HPA) axis during therapeutic management of active inflammatory bowel disease. Oral budesonide, at a dose of 3 mg/m(2), was administered once daily. Upon entry and completion of the trial, serum basal cortisol, adrenocorticotropic (ACTH)-stimulated cortisol, endogenous ACTH concentration, serum alkaline phosphatase (SAP) activity, and urine specific gravity were evaluated, as well as owner assessment of glucocorticoid-associated side effects. Significant suppression of the HPA axis occurred. No significant differences in SAP activity, urine specific gravity, or owner-subjective assessments were detected.

published proceedings

  • J Am Anim Hosp Assoc

author list (cited authors)

  • Tumulty, J. W., Broussard, J. D., Steiner, J. M., Peterson, M. E., & Williams, D. A

citation count

  • 20

complete list of authors

  • Tumulty, Joshua W||Broussard, John D||Steiner, Jörg M||Peterson, Mark E||Williams, David A

publication date

  • March 2004